Nasal delivery of high molecular weight drugs

Molecules

Volumn 14, Issue 9, 2009, Pages 3754-3779

  Ozsoy, Yildiz ^a   Gungor, Sevgi ^a   Cevher, Erdal ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Macromolecular drugs; Nasal delivery; Peptide; Protein; Vaccine

Indexed keywords

DRUG;

ANIMAL; DRUG DELIVERY SYSTEM; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOLECULAR WEIGHT; NOSE MUCOSA; REVIEW;

ADMINISTRATION, INTRANASAL; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR WEIGHT; NASAL MUCOSA; PHARMACEUTICAL PREPARATIONS;

EID: 70349556669     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14093754     Document Type: Review

References (110)

1. Ugwoke, M.I.; Verbeke, N.; Kinget, R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001, 53, 3-21.
2. Behl, C.R.; Pimplaskar, H.K.; Sileno, A.P.; deMeireles, J.; Romeo, V.D. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev. 1998, 29, 89-116.
3. Arora, P.; Sharma, S.; Garg, S. Permeability issues in nasal drug delivery. Drug Discov. Today 2002, 7, 967-975.
4. Cornaz, A.L.; Buri, P. Nasal Mucosa as an Absorption Barrier. Eur. J. Pharm. Biopharm. 1994, 40, 261-270.
5. Jones, N. The Nose and paranasal sinuses physiology and anatomy. Adv. Drug Deliv. Rev. 2001, 57, 5-19.
6. Sciarra, J.J. Remington: The Science and Practice of Pharmacy; Gennaro, A.R., Ed.; Mack Publishing Company: Easton, PA, USA, 1995; Chapter 95, p. 1676.
7. Sanders, P.; Washington, N.; Frier, M.; Wilson, C.G.; Feely, L.C.; Washington, C. The deposition of solution-based and suspension-based aerosols from metered dose inhalers in healthy subjects and asthmatic patients. S.T.P. Pharm. Sci. 1997, 7, 300-306.
8. Schipper, N.G.; Verhoef, J.C.; Merkus, F.W. The nasal mucociliary clearance: Relevance to nasal drug delivery. Pharm. Res. 1991, 8, 807-814.
9. Ingemann, M.; Frokjaer, S.; Hovgaard, L.; Brøndsted, H. Peptide and Protein Drug Delivery Systems for Non-Parenteral Routes of Administration. In Pharmaceutical Formulation Development of Peptides and Proteins; Frokjaer, S., Hovgaard, L., Eds.; Taylor & Francis: Philadelphia, PA, USA, 2000; Chapter 10, p.189.
10. Wermeling, D.P.; Miller, J.L. Intranasal Drug Delivery. In Modified Release Drug Delivery Technology; Rathbone, M.J., Hadgraft, J., Roberts, M.S., Eds.; Marcel Dekker, Inc.: New York, NY, USA, 2002; Chapter 61, p. 727.
11. Ungell, A.L.; Andreasson, A.; Lundin, K.; Utter, L. Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat. J. Pharm. Sci. 1992, 87, 640-645.
12. Corbo, D.C.; Liu, J.C.; Chien, Y.W. Drug absorption through mucosal membranes: Effect of mucosal route and penetrant hydrophilicity. Pharm. Res. 1989, 6, 848-852.
13. McMartin, C.; Hutchinson, L.E.; Hyde, R.; Peters, G.E. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 1987, 76, 535-540.
14. Tuma, P.L.; Hubbard, L. Transcytosis: Crossing cellular barriers. Physiol. Rev. 2003, 83, 871-932.
15. Illum, L. Nasal Drug delivery-possibilities, problems and solutions. J. Control. Release 2003, 87, 187-198.
16. Hussain, A.A. Intranasal drug delivery. Adv. Drug Deliv. Rev. 1998, 29, 39-49.
17. O'Hagan, D.T.; Illum, L. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Syst. 1990, 7, 35-97.
18. Irwin, W.J.; Dwivedi, A.K.; Holbrook, P.A.; Dey, M.J. The Effect of cyclodextrins on the stability of peptides in nasal enzymic systems. Pharm. Res. 1994, 11, 1698-1703.
19. Morita, T.; Yamahara, H. Encyclopedia of Pharmaceutical Technology, 3rd ed.; Swarbrick, J., Ed.; Informa Healthcare: London, UK, 2007; Vol.4, p. 2678.
20. Stolnic, S.; Shakesheff, K. Formulation for delivery the therapeutics proteins. Biotechnol. Lett. 2009, 31, 1-11.
21. Romeo, V.D.; deMeireles, J.C.; Gries, W.J.; Xia, W.J.; Sileno, A.P.; Pimplaskar, H.K.; Behl, C.R. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv. Drug Deliv. Rev. 1998, 29, 117-133.
22. Sarkar, M.A. Drug Metabolism in the nasal mucosa. Pharm. Res. 1992, 9, 1-9.
23. Ozsoy, Y.; Tuncel, T.; Can, A.; Akev, N.; Birteksöz, S.; Gerçeker, A. In vivo studies on nasal preparations of ciprofloxacin hydrochloride. Pharmazie 2000, 55, 607-609.
24. Davis, S.S.; Illum, L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. 2003, 42, 1107-1128.
25. Law, S.L.; Huang, K.J.; Chou, H.Y. Preparation of desmopressin-containing liposomes for intranasal delivery. J. Control. Release 2001, 70, 375-382.
26. Mitra, R.; Pezron, I.; Chu, W.A.; Mitra, A.K. Lipid emulsions as vehicles for enhanced nasal delivery of insulin. Int. J. Pharm. 2000, 205, 127-134.
27. Kumar, M.; Pathak, K.; Misra, A. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev. Ind. Pharm. 2009, 35, 387-395.
28. Gungor, S.; Okyar, A.; Erturk-Toker, S.; Baktir, G.; Ozsoy, Y. Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: In vitro/in vivo studies. Pharm. Dev. Tech. 2009, doi: 10.1080/10837450903148257.
29. Gungor, S.; Okyar, A.; Erturk-Toker, S.; Baktir, G.; Ozsoy, Y. In Vitro and in Vivo Studies on Ondansetron HCl-Loaded Chitosan Microspheres for Nasal Drug Delivery. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Barcelona, Spain, 7-10 April 2008.
30. Brooking, J.; Davis, S.S.; Illum, L. Transport of nanoparticles accross the rat nasal mucosa. J. Drug Target. 2001, 9, 267-279.
31. McGinity, J.W.; O'Donnell, P.B. Preparation of microspheres by the solvent evaporation technique. Adv. Drug Deliv. Rev. 1997, 28, 25-42.
32. Rajaonarivony, M.; Vauthier, C.; Couarraze, G.; Puisieux. F.; Couvreur, P. Development of a new drug carrier made from alginate. J. Pharm. Sci. 1993, 82, 912-917.
33. Chowdary, K.P.; Rao, Y.S. Mucoadhesive microspheres for controlled drug delivery. Biol. Pharm. Bull. 2004, 27, 1717-1724.
34. Agnihotri, S.A.; Mallikarjuna, N.N.; Aminabhavi, T.M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release 2004, 100, 5-28.
35. Ozsoy Y. In Handbook of Particulate Drug Delivery; Kumar, M.N.V.R., Ed.; American Scientific Publisher: Stevenson Ranch, CA, USA, 2008; Vol.2, Chapter 8, p.143.
36. van der Lubben, I.M,; Verhoef, J.C.; Borchard, G.; Junginger, H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 2001, 74, 201-207.
37. Wong, T.W. Chitosan and its use in design of insulin delivery system. Recent Pat. Drug Deliv. Formul. 2009, 3, 8-25.
38. Henriksen, I.; Green, K.L.; Smart, J.D.; Smistad, G.; Karlsen, J. Bioadhesion of hydrated chitosan: An in vitro and in vivo study. Int. J. Pharm. 1996, 745, 231-240.
39. Schipper, N.G.; Olsson, S.; Hoogstraate, J.A.; deBoer, A.G.; Varum, K.M.; Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs 2: Mechanism of absorption enhancement. Pharm. Res. 1997, 74, 923-929.
40. Lehr, C.M.; Bouwstra, J.A.; Schacht, E.H.; Junginger, H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 1992, 78, 43-48.
41. Artursson, P.; Lindmark, T.; Davis, S.S.; Illum, L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 1994, 77, 1358-1361.
42. Alpar, H.O.; Eyles, J.E.; Williamson, E.D.; Somavarapu, S. Intranasal vaccination against plague, tetanus and diphtheria. Adv. Drug Deliv. Rev. 2001, 57, 173-201.
43. Vila, A.; Sánchez, A.; Tobío, M.; Calvo, P.; Alonso, M.J. Design of biodegradable particles for protein delivery. J. Control. Release 2002, 78, 15-24.
44. Vila, A.; Sánchez, A.; Evora, C.; Soriano, I.; Vila Jato, J.L.; Alonso, M.J. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J. Aerosol. Med. 2004, 77, 174-185.
45. Farraj, N.F.; Johansen, B.R.; Davis, SS.; Illum, L. Nasal administration of insulin using bioadhesive microspheres as a delivery system. J. Control. Release 1990, 73, 253-261.
46. Björk, E.; Edman, P. Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int. J. Pharm. 1990, 62, 187-192.
47. Edman, P.; Björk, E.; Ryden, L. Microspheres as a nasal delivery system for peptide drugs. J. Control. Release 1992, 27, 165-172.
48. Callens, C.; Remon, J.P. Evaluation of starch-maltodextrin-carbopol 974 P mixtures for the nasal delivery of insulin in rabbits. J. Control. Release 2000, 66, 215-220.
49. Illum, L.; Fisher, A.N.; Jabbal-Gill, I.; Davis, S.S. Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int. J. Pharm. 2001, 222, 109-119.
50. Callens, C.; Pringels, E.; Remon, J.P. Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. Int. J. Pharm. 2003, 250, 415-422.
51. Pringels, E.; Vervaet, C.; Verbeeck, R.; Foreman, P.; Remon, J.P. The addition of calcium ions to starch/carbopol mixtures enhances the nasal bioavailability of insulin. Eur. J. Pharm. Biopharm. 2008, 68, 201-206.
52. Jain, A.K.; Khar, R. K.; Ahmed, F. J.; Diwan, P.V. Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur. J. Pharm. Biopharm. 2008, 69, 426-435.
53. Pereswetoff-Morath, L.; Edman, P. Dextran microspheres as a potential nasal drug delivery system for insulin-in vitro and in vivo properties. Int. J. Pharm. 1995, 724, 37-44.
54. Takenaga, M.; Serizawa, Y.; Azechi, Y.; Ochiai, A.; Kosaka, Y.; Igarashi, R.; Mizushima, Y. Microparticle resins as a potential nasal drug delivery system for insulin. J. Control. Release 1998, 52, 81-87.
55. Illum, L.; Farraj, N.F.; Fisher, A.N.; Gill, I.; Miglietta, M.; Benedetti, L.M. Hyaluronic acid ester microspheres as a nasal delivery system for insulin. J. Control. Release 1994, 29, 133-141.
56. Fernandez-Urrusuno, R.; Romani, D.; Calvo, P.; Vila-Jato, J.L.; Alonso, M.J. Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. S.T.P. Pharma. Sci. 1999, 9, 429-436.
57. Varshosaz, J.; Sadrai, H.; Alinagari, R. Nasal delivery of insulin using chitosan microspheres. J. Microencapsul. 2004, 21, 761-774.
58. Krauland, A.H.; Leitner, V.M.; Grabovac, V.; Bernkop-Schnürch, A. In vivo evealuation of a nasal insulin delivery system based on thiolated chitosan. J. Pharm. Sci. 2006, 95, 2463-2472.
59. Krauland, A.H.; Alonso, M.J. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int. J. Pharm. 2007, 340, 134-142.
60. Bhumkar, D.R.; Joshi, H.M.; Sastry, M.; Pokharkar, V.B. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm. Res. 2007, 24, 1415-1426.
61. Wang, X.; Zheng, C.; Wu, Z.; Teng, D.; Zhang, X.; Wang, Z.; Li, C. Chitosan-NAC nanoparticles as a Vehicle for nasal absorption enhancement of insulin. J. Biomed. Mater. Res. 2009, 88, 150-161.
62. Teijeiro-Osorio, D.; Remunán-López, C.; Alonso, M.J. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009, 10, 243-249.
63. Wang, J.; Tabata, Y.; Morimoto. K. Aminated gelatin microspheres as a nasal delivery system for peptide drugs: Evaluation of in vitro release and in vivo absorption in rats. J. Control. Release 2006, 113, 31-37.
64. Khafagy, E.S.; Morishita, M.; Isowa, K.; Imai, J.; Takayama, K. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release 2009, 133, 103-108.
65. Moeller, E.M.; Jorgensen, L. Alternative routes of administration for systemic delivery of protein pharmaceuticals. Drug Discov. Today Technol. 2008, doi:10.1016-j.ddtec.2008.11.005.
66. Critchley, H.; Davis, S.S.; Farraj, N.F.; Illum, L. Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J. Pharm. Pharmacol. 1994, 46, 651-656.
67. Fransén, N.; Bredenberg, S.; Björk, E. Clinical study shows improved absorption of desmopressin with novel formulation. Pharm. Res. 2009, 26, 1618-1625.
68. Morimoto, K.; Katsumata, H.; Yabuta, T.; Iwanaga, K.; Kakemi, M.; Tabata, Y.; Ikada, Y. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur. J. Pharm. Sci. 2001, 13, 179-185.
69. Hinchcliffe, M.; Jabbal-Gill, I.; Smith, A. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. J. Pharm. Pharmacol. 2005, 57, 681-687.
70. Lee, K.C.; Park, M.O.; Na, D.H.; Youn, Y.S.; Lee, S.D.; Yoo, S.D.; Lee, H.S.; DeLuca, P.P. Intranasal delivery of pegylated salmon calcitonins: Hypocalcemic effects in rats. Calcif. TissueInt. 2003, 73, 545-549.
71. Ishikawa, F.; Katsura, M.; Tamai, I.; Tsuji, A. Improved nasal bioavailability of elcatonin by insoluble powder formulation. Int. J. Pharm. 2001, 224, 105-114.
72. Lee, W.A.; Ennis, R.D.; Longenecker, J.P.; Bengtsson, P. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm. Res. 1994, 77, 747-750.
73. Pontiroli, A.E.; Pajetta, E; Calderara, A.; Alberetto, M.; Pozza, G.; Manganelli, V.; Resmini, G.; Tessari, L.; Maresca, V. Intranasal and intramuscular human calcitonin in female osteoporosis and in paget's disease of bones: A pilot study. J. Endocrinol. Invest. 1991, 74, 47-51.
74. Matsuyama, T.; Morita, T.; Horikiri, Y.; Yamahara, H.; Yoshino, H. Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. J. Control. Release 2006, 775, 183-188.
75. Matsuyama, T.; Morita, T.; Horikiri, Y.; Yamahara, H.; Yoshino, H. Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant. J. Control. Release 2006, 770, 347-352.
76. Adjei, A.; Sundberg, D.; Miller, J.; Chun, A. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. 1992, 9, 244-249.
77. Abe, K.; Irie, T.; Uekama, K. Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin. Chem. Pharm. Bull. 1995, 43, 2232-2237.
78. Illum, L.; Watts, P.; Fisher, A.N.; Jabbal Gill, I.; Davis, S.S. Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue. S.T.P. Pharma Sci. 2000, 70, 89-94.
79. Illum, L.; Farraj, N.F.; Davis, S.S.; Johansen, B.R.; O'Hagan, D.T. Investigation of the nasal absorption of biosynthetic human growth hormone in sheep - use of a bioadhesive microsphere delivery system. Int. J. Pharm. 1990, 63, 207-211.
80. Laursen, T.; Grandjean, B.; Jorgensen, J.O.; Christiansen, J.S. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: Comparison with intravenous and subcutaneous administration. Eur. J. Endocrinol. 1996, 735, 309-315.
81. Agerholm, C.; Bastholm, L.; Johansen, P.B.; Nielsen M.H.; Elling, F. Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers idecanoyl-L-alpha- phosphatidylcholine and Alpha-cyclodextrin in rabbits. J. Pharm. Sci. 1994, 83, 1706-1711.
82. Hedin, L.; Olsson, B.; Diczfalusy, M.; Flyg, C.; Petersson, A.S.; Rosberg, S.; Albertsson- Wikland, K. Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: A pharmacokinetic study. J. Clinical Endocrinol. Metab. 1993, 76, 962-967.
83. Leitner, V.M.; Guggi, D.; Krauland, A.H.; Bernkop-Schnürch, A. Nasal Delivery of human growth hormone: In vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J. Control. Release 2004, 700, 87-95.
84. Vancheri, C.; Mastruzzo, C.; Armato, F.; Tomaselli, V.; Magrì, S.; Pistorio, M.P.; LaMicela, M.; D'Amico, L.; Crimi, N. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J. Allergy Clin. Immunol. 2001, 708, 703-708.
85. Zeng, D.; Prosperini, G.; Russo, C.; Spicuzza, L.; Cacciola, R.R.; Di Maria, G.U.; Polosa, R. Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation. J. Allergy Clin. Immunol. 2004, 774, 316-320.
86. Yildiz, A.; Okyar, A.; Baktir, G.; Araman, A.; Ozsoy, Y. Nasal administration of heparin-loaded microspheres based on poly(lactic acid). Il Farmaco 2005, 60, 919-924.
87. Arnold, J.; Ahsan, F.; Meezan, E.; Pillion, D.J. Nasal administration of low molecular weight heparin. J. Pharm. Sci. 2002, 97, 1707-1714.
88. Yang, T.; Hussain, A.; Paulson, J.; Abbruscato, T.J.; Ahsan, F. Cyclodextrins in nasal delivery of low-molecular-weight heparins in vivo and in vitro studies. Pharm. Res. 2004, 21, 1127-1136.
89. Mustafa, F.; Yang, T.; Khan, M.A.; Ahsan, F. Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin. J. Pharm. Sci. 2004, 93, 675-683.
90. Yang, T.; Mustafa, F.; Ahsan, F. Alkanoylsucroses in nasal delivery of low molecular weight heparins: In vivo absorption and reversibility studies in rats. J. Pharm. Pharmacol. 2004, 56, 53-60.
91. Yang, T.; Hussain, A.; Bai, S.; Khalil, I.A.; Harashima, H.; Ahsan, F. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin. J. Control. Release 2006, 775, 289-297.
92. Li, Y.; Jiang, H.L.; Zhu, K.J.; Liu, J.H.; Hao, Y.L. Preparation, characterization and nasal delivery of α-cobrotoxin-loaded poly(lactide-co-glycolide)/polyanhydride microspheres. J. Control. Release 2005, 708, 10-20.
93. Gedulin, B.R.; Smith, P.A.; Jodka, C.M.; Chen, K.; Bhavsar, S.; Nielsen, L.L.; Parkes, D.G.; Young, A.A. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int. J. Pharm. 2008, 356, 231-238.
94. Teshima, D.; Yamauchi, A.; Makino, K.; Kataoka, Y.; Arita, Y.; Nawata, H.; Oishi, R. Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int. J. Pharm. 2002, 233, 61-66.
95. Zhang, Y.; Zhang, Q.; Sun, Y.; Sun, J.; Wang, X.; Chen, M. Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies. Biol. Pharm. Bull. 2005, 28, 2263-2267. (Pubitemid 41757417)
96. Kissel, T.; Drewe, J.; Bantle, S.; Rummelt, A.; Beglinger, C. Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. Pharm. Res. 1992, 9, 52-57.
97. Oechslein, C.R.; Fricker, G.; Kissel, T. Nasal delivery of octreotide: absorption enhancement by particulate carrier systems. Int. J. Pharm. 1996, 739, 25-32.
98. Davis, S.S. Nasal vaccines. Adv. Drug. Deliv. Rev. 2001, 57, 21-42.
99. Gutierro, I.G.; Hernandez, R.M. ; Igartua, M.; Gascon, A. R.; Pedraz, J. L. Influence of dose and immunization route on the serum IgG antibody response to BSA loaded PLGA microspheres. Vaccine 2002, 20, 2181-2190.
100. Olszewska, W.; Steward, M.W. Nasal delivery of epitope based vaccines. Adv. Drug Deliv. Rev. 2001, 57, 161-171.
101. Vyas, S.P.; Gupta, P.N. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines 2007, 6, 401-418.
102. Sharma, S.; Mukkur, T.K.S.; Benson, H.A.E.; Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 2009, 98, 812-843.
103. Singh, M.; Chakrapani, A.; O'Hagan, D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 2007, 6, 797-808.
104. Csaba, N.; Gargia-Fuentes, M.; Alonso, M.R. Nanoparticles for nasal vaccination. Adv. Drug. Del. Rev. 2009, 61, 140-157.
105. Alpar, H.O.; Özsoy, Y.; Bowen, J.; Eyles, J.E.; Conway, B.R.; Williamson, E.D. Potential of Particulate carriers for the mucosal delivery of dna vaccines. Biochem. Soc. Trans. 1997, 25, 337S.
106. Salomon, S.K.; Cevher, E.; Somavarapu, S.; Li, X.W.; Brocchini, S.; Sesardic, T.; Alpar, H.O. Novel N-Trimethyl Chitosan- Poly(γ-Glutamic Acid) Nanoparticles for Mucosal Delivery of Vaccines. 34th Annual Meeting & Exposition of the Controlled Release Society, Long Beach, CA, USA, 7-11 July 2007.
107. Singh, J.; Pandit, S.; Bramwell, V.W.; Alpar, H.O. Diphtheria toxoid loaded poly-(epsilon- caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 2006, 38, 96-105.
108. Illum, L.; Jabbal-Gill, I.; Hincgcliffe, M.; Fisher, A.N.; Davis, S.S. Chitosan as a novel delivery system for vaccines. Adv. Drug. Del. Rev. 2001, 51, 81-96.
109. Vila, A.; Sánchez, A.; Janes, K.; Behrens, I.; Kissel, T.; Vila Jato, J.L.; Alonso, M.J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 2004, 57, 123-131.
110. Jung, T.; Kamm, W.; Breitenbach, A.; Hungerer, K.D.; Hundt, E.; Kissel, T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): Evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 2001, 18,352-360.